Company

Protalix BioTherapeutics, Inc.

Headquarters: Karmiel, Israel

Founded: 1993

Employees: 207

CEO: Mr. Dror Bashan

TASE: PLX +0.96%

Market Cap

₪292.9 Million

ILS as of Jan. 1, 2023

US$83.6 Million

Market Cap History

Protalix BioTherapeutics, Inc. market capitalization over time

Evolution of Protalix BioTherapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Protalix BioTherapeutics, Inc.

Detailed Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Protalix BioTherapeutics, Inc. has the following listings and related stock indices.


Stock: TASE: PLX wb_incandescent

Stock: NYSE: PLX wb_incandescent

Stock: FSX: PBDA wb_incandescent

Product & Services

Elelyso

Key People

Founder(s): Yoseph Shaaltiel

Shlomo Yanai (Interim Chairman) Moshe Manor (CEO)

Financials

Revenue: $11.51 million (2013)


Total assets: $113.33 million (2013)

Details

Headquarters:

2 Snunit Street

Science Park PO Box 455

Karmiel, 2161401

Israel

Phone: 972 4 988 9488

Fax: 972 4 988 9489